Home Infusion Therapy Market Size, Share & Covid-19 Impact Analysis, By Product (Devices, Drugs, and Services) By Indication (Anti-Infective, Chemotherapy, Hydration Therapy, Enteral Nutrition, Total Parenteral Nutrition, Immunoglobulin Therapy, and Others), and Regional Forecast, 2020-2027

This report covers COVID-19 impact analysis on Home Infusion Therapy Market

Inquire before buying

According to the Centers for Medicare & Medicaid Services (CMS), there were an estimated 11,869 certified home health agencies in the U.S., in 2018. Also, according to the CMS, home health services are covered under the Medicare benefit program. Home infusion therapy is defined as a process in which patients receive biologics & drugs at home. This also includes nursing services that provide, train, and educates patients about the safe intravenous administration of drugs. Receiving care at home rather than a healthcare facility or other care settings has become a cost-effective option for patients, and has reduced hospital costs, which is playing a vital role in boosting the demand for this therapy across the globe. Various government initiatives are being implemented, for shifting patients towards home care, to reduce the overall hospitalization, and treatment cost. Additionally, the rise in preference for homecare among patients especially for infusion therapy, and the growing developments in home infusion therapy devices for designed for home use are some factors likely to drive the market.

Shift towards Homecare Settings amid Covid-19 Pandemic

Amid the ongoing coronavirus outbreak, various countries have delayed or postponed all elective procedures. Although infusion therapy is not elective, the presence of home infusion alternative as opposed to infusion therapy at hospitals has limited the intake of such patients in hospital settings. The primary reason includes hospitals being overburdened by the COVID-19 patients, and a majority of resources being diverted for the management of COVID-19 pandemic. Due to this, a majority of patients are shifting towards home-based care to continue infusion therapies. This has led to an increase in the number of patients receiving infusion therapy at home in 2020. Many home infusion service providers such as Option Care Health Inc., are working in collaboration with hospitals to facilitate the shift of patients at home care settings to receive treatment. Additionally, the home infusion service providers are building a strong network with pharmacies to develop a personalized development care plan and provide customized medications & supplies to patients in need of infusion therapies at home. These factors have exerted a positive impact on demand for home infusion supplies, and services, especially in developed countries.

The implementation of regulations by the Centers for Medicare & Medicaid Services (CMC), has waived off the need for nurses and physicians to visit patients at home and have directed the visits to be held via Telehealth platforms. The virtual patient handling offers certain drawbacks as it becomes difficult for caregivers to obtain import data through a video call. This is anticipated to slightly hinder the uptake of infusion therapy at home, especially among hospitalized patients. However, initiatives taken by various governments for the development of new reimbursement policies, providing cost-effective infusion products & services to the patients at home are likely to pose a positive impact on the market during coronavirus pandemic.

LATEST TRENDS

Request a sample to learn more about this report.

Dramatic Shift towards Home Medical Care likely to Boost Market Growth

As the healthcare sector is evolving at a rapid pace, patient care is now being delivered outside the hospital settings. There is a gradual shift of patients and healthcare providers for the treatment of non-critical conditions in outpatient settings, including home care settings. Various for-profit and private companies have entered the service sector, and are training medical personnel for the delivery of infusion therapy benefits to patients at home. Various comparative studies have demonstrated a significant cost reduction for providing specialty infusion drugs in homes as compared to hospital settings. According to a randomized study performed in a French hospital to evaluate the cost of IVIG infusion at a hospital vs. home care setting, the total cost of IVIG infusion per patient in a hospital setting was estimated to be around USD 11,450, as compared to USD 5,710 spent in homecare settings. This has been pivotal in attracting a large patient pool towards adopting therapy at home as a preferred choice of treatment. Along with this, efforts were undertaken by many healthcare organizations in promoting homecare and an increase in the number of players offering a wide range of services, is anticipated to increase the demand for home infusion products & services during the forecast period.

DRIVING FACTORS

Growing Prevalence of Chronic Disease and Rise in Geriatric Population to Fuel Demand

The burden of chronic diseases is rapidly increasing globally. There has been a tremendous rise in the incidences of chronic immune deficiencies, cancer, diabetes, and congestive heart failure, etc. According to the World Health Organization (WHO), the prevalence of the chronic disease is anticipated to rise by 57% by the year 2020. Another major factor driving the market is the rapidly increasing geriatric population. According to the United Nations (UN), the number of people above 60 years is projected to grow by 56%, from 901 million in 2015 to 1.4 billion in 2030. This is anticipated to result in a large pool of patients suffering from chronic diseases, along with patients undergoing infusion therapy at home settings.

Growing awareness about the benefits associated with home treatment modality and rapid technological advancements in the devices designed for home use are some of the additional factors likely to fuel the adoption of  home infusion therapy globally during the forecast period.

Demand for Personalized Intravenous Drug Infusion Therapy to Augment Growth.

The increasing prevalence of hospital-acquired infections is one of the major factors promoting the home infusion therapy market growth. Globally, hospital-acquired infection is on the rise owing to the prolonged inpatient hospital stays and has currently become one of the major safety concerns among healthcare providers. According to the Centers for Disease Control (CDC) an estimated 1.7 million patients in the U.S. are infected with the hospital-acquired infection every year. The immune-compromised patients receiving infusion therapy at hospitals are at greater risk, making home care setting the best alternative option to receive safe treatment, further augmenting the preference towards home infusion therapy among patients.

RESTRAINING FACTORS

Limited Reimbursement for Homecare to Restrict Market Growth

One of the major factors likely to hinder the market growth is the lack of reimbursement policies in many developing nations. The out-of-pocket expenditure on healthcare in emerging countries such as China and India is higher compared to other countries with an established reimbursement structure. The situation is further compounded by the lack of reimbursement policies for home care settings in these countries. This has limited the number of patients undergoing home infusion therapies in emerging countries. This, along with a limited number of public and private home infusion providers in emerging countries, lack of trained medical personnel, and other limited resources, is expected to limit the adoption of these services. 

SEGMENTATION

By Product Analysis

To know how our report can help streamline your business, Speak to Analyst

Robust Drug Pipeline Likely to Support Drugs Segment Dominate Market

Based on product type, the market is segmented into devices, drugs, and services. The drug segment held the largest home infusion therapy market share in 2019. The growing incidence of cancer, and various immune diseases worldwide and the strong infused drug pipeline is likely to boost the growth of the drug segment during the forecast period. The service segment is anticipated to witness significant growth during the forecast period accountable to the rise in the number of healthcare professionals and an increase in the number of services offered by many players. The devices segment is likely to witness second-highest growth after services segment during the forecast period owing to the rise in the number of entrants in the market and growing technological advancements in the home infusion medication delivery systems for various indications.

By Indication Analysis

Rising Awareness about the benefits of Receiving Chemotherapy at Home is anticipated to boost the Chemotherapy Segment Growth during Forecast Period

In terms of indication the market is segmented into anti-infective, chemotherapy, hydration therapy, enteral nutrition, parenteral nutrition, intravenous immunoglobulin, and others. The anti-infective segment dominated the market in 2019 owing to the higher prevalence of infectious diseases, ease of set-up for anti-infective infusion therapy, and its low cost. Moreover, the usage of anti-infective therapies after every other infusion therapy to reduce the chances of catheter line infection in patients is further propelling the popularity of this segment. The chemotherapy segment is anticipated to witness the highest growth during the forecast period. The massive increase in the prevalence of cancer worldwide and the rise in the awareness about the benefits of chemotherapy at home is likely to accelerate the growth of the chemotherapy segment in the future. According to the American Cancer Society, an estimated 1.7 million new cancer cases were registered in the U.S. alone in 2018. The intravenous immunoglobulin therapy segment is anticipated to witness strong growth over the forecast period owing to the rise in prevalence of primary immunodeficiency diseases such as hypogammaglobinemia and congenital AIDS coupled with new SCIG product approvals of immunoglobulin.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a sample

This market size in North America stood at USD 10.53 billion in 2019 owing to the rapid adoption of therapy and the presence of key players in this region. Moreover, a growing number of patients opting for infusion therapy at home is likely to boost the market in the region. According to a report published by the National Home Infusion Association (NHIA) in 2016, around 80,000 patients in the U.S. receive home infusions each year for various indications. The market in Asia Pacific is projected to witness significant growth by registering the highest CAGR during the forecast period. This is attributed to the growing awareness about this therapy used for the treatment of a wide range of chronic disorders and the rise in the adoption of innovative technologies. Moreover, the increasing prevalence of chronic diseases such as cancer, diabetes, and other long term chronic diseases and rise in the patient pool are likely to boost the market in Asia Pacific during the forecast period.

KEY INDUSTRY PLAYERS

Strong Product Portfolio of  Optum, Inc., Option Care Health Inc., Baxter, and B. Braun Melsungen AG to Help Strengthen their Position in Market

The competitive landscape of the market is consolidated with the presence of a handful of players such as Optum, Inc., Option Care Health Inc., Baxter, and B. Braun Melsungen AG. The players are majorly focused on the development of innovative infusion pumps and emphasis on expanding their geographical footprints in both domestic & international markets. Moreover, small market manufacturers are focusing on expanding their base in emerging nations, thereby focusing on the development of a relatively large number of delivery devices and supplies for homecare health settings.             

LIST OF KEY PLAYERS PROFILED:

• Option Care Health Inc. (Illinois, U.S.)


• Optum, Inc.  (Minnesota, U.S.)


• CareCentrix, Inc. (Hartford, U.S.)


• Lincare Holdings Inc. (Florida, U.S.)


• BriovaRx Infusion Services   (Houston, U.S.)


• Fresenius SE & Co. KGaA (Bad Homburg, Germany)


• Baxter International (Deerfield, Illinois, U.S.)


• B. Braun Melsungen AG (Melsungen, Germany)


• Terumo Corporation (Tokyo, Japan)


• Moog Inc.  (New York, U.S.)


• Others

KEY INDUSTRY DEVELOPMENTS:

• December 2019 –   Optum, Inc. announced the collaboration with Diplomat, a provider of specialty pharmacy and infusion services to enhance the specialty and infusion services for patients with chronic diseases, such as oncology and immunology in U.S.


• August 2019 –   Option Care Health Inc. and BioScrip announce the successful completion of their mergers. The aim of the merging war to establishes the standard of care through its clinical leadership and technology-enabled patient-centered model across United States.

REPORT COVERAGE

The home infusion therapy market report provides a detailed analysis of the market and focuses on key aspects such as the global prevalence of chronic diseases, technological advancements in infusion drug delivery devices, and others. Besides this, the report offers insights into the market, current trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over the recent years.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation